Refractory immune thrombocytopenia successfully treated with bortezomib in a child with 22q11.2 deletion syndrome, complicated by Evans syndrome and hypogammaglobulinemia

Refractory immune thrombocytopenia successfully treated with bortezomib in a child with 22q11.2 deletion syndrome, complicated by Evans syndrome and hypogammaglobulinemia

Treatment of refractory autoimmune cytopenias (AICs) and Evans syndrome (ES) represent a great challenge in pediatric setting, where an underlying primary immunodeficiency is recurrent. Frequently, second or third line treatments are employed, with an increased risk of toxicity and infections. The a...

Full description

Bibliographic Details
Main Authors: Francesca Conti, Francesca Gottardi, Mattia Moratti, Tamara Belotti, Simona Ferrari, Paola Selva, Mirna Bassi, Daniele Zama, Andrea Pession
Format: Article
Language:English
Published: Taylor & Francis Group 2022-07-01
Series:Platelets
Subjects:
bortezomib
evans syndrome
immune thrombocytopenia, pediatrics
Online Access:http://dx.doi.org/10.1080/09537104.2021.2002835

Internet

http://dx.doi.org/10.1080/09537104.2021.2002835

Similar Items